Tirzepatide Cost Without Insurance (2026 Cash Prices Explained)

Tirzepatide produced some of the largest average weight losses ever seen in obesity drug trials. It also comes with a list price above $1,000 a month. Since 2024, Eli Lilly has sold Zepbound, the weight-management version of tirzepatide, directly to self-paying patients at much lower prices, and in 2026 those prices, formats and rules changed again. This guide lays out what you would actually pay without insurance, where the fine print hides, and how to build a realistic 12-month budget.

Prices and offers change. Figures below come from Lilly’s public self-pay pages and program terms, CMS and Medicare.gov, as reviewed on October 21, 2026. Confirm current terms before you pay. This is general information, not medical, financial or tax advice.

The short answer

Without insurance, FDA-approved tirzepatide for weight management costs $299 to $449 a month through Lilly’s self-pay program for most people who refill on time. The lowest price is for the 2.5 mg starting dose. Higher doses cost more, and the $449 price for 7.5 mg and above only holds if you refill within 45 days. Miss that window and a month at 10 mg or more costs $699.

Two other facts shape the real total:

• A “month” is 28 days. That means 13 fills a year, not 12.
• The medicine price is not the whole bill. Needles or syringes, taxes, and the clinician or telehealth fee for the prescription are extra.

If you have Medicare Part D and meet the criteria, the picture is very different: a $50 monthly copay through the temporary Medicare GLP-1 Bridge (more on that below).

Zepbound self-pay prices by dose (October 2026)

Zepbound comes in three formats: the single-dose autoinjector pen, single-dose vials, and the newer KwikPen, which holds four weekly doses in one pen. Lilly’s self-pay prices apply to the vials and the KwikPen. According to LillyDirect and Lilly’s program terms:

Dose	Self-pay price per 28-day month (refill within 45 days)	Regular price (refill after 45 days)
2.5 mg (starting dose)	$299	$299
5 mg	$399	$399
7.5 mg	$449	$499
10 mg	$449	$699
12.5 mg	$449	$699
15 mg	$449	$699

A few details from the terms matter for budgeting:

• One month means 28 days and either four single-dose vials or one KwikPen.
• The $449 offer for 7.5 mg to 15 mg is called the Zepbound Self Pay Journey Program. You receive it automatically on your first purchase at those doses, and new and existing patients are both eligible.
• Lilly notes that 2.5 mg is a starting dose and is not approved as a maintenance dose, so almost nobody stays at the cheapest price for long.
• Lilly says it can change or end these offers at any time, and taxes and fees may apply.

In short, the self-pay price climbs with the dose during the first few months and then levels off at $449, provided refills stay on schedule.

The 45-day refill rule, in plain terms

The single most expensive mistake in tirzepatide budgeting is a late refill at a higher dose.

Lilly’s terms say you must complete each refill purchase within 45 days of the delivery or receipt date of your previous vial or KwikPen order to keep the $449 price. If more than 45 days pass, that fill is charged at the regular price: $499 for 7.5 mg, or $699 for 10, 12.5 or 15 mg.

Because a month’s supply covers 28 days, the rule leaves about two and a half weeks of slack. Gaps happen for ordinary reasons: travel, a delayed prescription renewal, a shipping problem, or a pause your clinician recommends because of side effects. If you expect a gap, it is worth asking your prescriber and the pharmacy ahead of time how it would affect both your dose plan and your price. Any decision to pause or restart treatment belongs with your clinician, not with the price list.

Vial, KwikPen or single-dose pen: what is the difference for your wallet?

The medicine inside is the same. The cost and the logistics differ.

Format	Where you can buy it self-pay	Self-pay price	What else you need
Single-dose vials (4 per month)	LillyDirect only	$299–$449 (as above)	A new syringe and needle for each dose
KwikPen (4 doses in 1 pen)	LillyDirect, or retail pharmacies with Lilly’s KwikPen self-pay savings card	$299–$449 (as above)	A new pen needle for each dose
Single-dose autoinjector pen (4 per month)	Mainly through insurance	Not part of the self-pay price list	Nothing extra

Lilly announced on March 16, 2026 that self-pay pricing for the KwikPen would be available “at LillyDirect and major pharmacies nationwide.” The KwikPen self-pay card, found on Lilly’s Zepbound savings page, works for adults with a valid on-label prescription, including people without insurance. Lilly states the card does not apply to vials or the single-dose pen.

Why this matters: if you walk into a retail pharmacy with a KwikPen prescription and do not present the self-pay card, you may be quoted a much higher cash price. Ask the pharmacist to run the card before you pay.

The vial-versus-pen choice is also about routine. In one YouTube video, a patient who had used both formats described the vial as more preparation (warming it up, drawing the dose, reading small syringe markings) and the KwikPen as quicker once she learned it, though she found it injected slowly. Injection technique is something your prescriber or pharmacist should teach you, whichever format you use.

What the first year can cost: three example budgets

Zepbound’s label describes starting at 2.5 mg once weekly and increasing in steps, with the dose decided by your clinician based on response and tolerability. Because doses differ from person to person, the examples below are illustrations of the arithmetic only, not dosing advice. Each uses 13 fills of 28 days.

Example	Fills	Medicine cost for the year
A: one month at 2.5 mg, then 12 months at 5 mg	$299 + 12 × $399	$5,087
B: one month each at 2.5 mg and 5 mg, then 11 months at 7.5 mg or higher, always refilled on time	$299 + $399 + 11 × $449	$5,637
C: same as B, but every refill at 10 mg or higher arrives late	$299 + $399 + $449 (7.5 mg) + 10 × $699	$8,137

Two things stand out. First, staying at a lower maintenance dose does not save much compared with the $449 tier, because 5 mg costs $399. Second, the difference between examples B and C is $2,500 for the same medicine, purely because of refill timing.

Add the extras on top:

• Needles or syringes for every dose (Lilly lists them as a separate purchase).
• Prescriber visits or a telehealth membership. Some programs charge per visit; others charge monthly.
• Lab work if your clinician orders it.
• Sales tax and fees, which Lilly’s terms say may apply.

Our GLP-1 costs hub collects the other pieces of the budget, including how telehealth pricing is structured.

If you have commercial insurance

“Without insurance” often really means “my insurance won’t pay for this.” Lilly’s 2026 savings terms treat those situations differently:

• Your plan covers the Zepbound single-dose pen: you may pay as little as $25 for a 1-, 2- or 3-month fill. Savings are capped at $100 per month (or $200 and $300 for 2- and 3-month fills) and $1,300 per calendar year, with a maximum of 13 fills. The card expires December 31, 2026. If your plan’s copay is high, the caps mean you could still owe more than $25.
• Your plan does not cover the KwikPen: the KwikPen self-pay card gives you the same self-pay prices as LillyDirect.
• Alternate funding programs: Lilly’s terms exclude patients whose plans use certain “alternate funding” arrangements tied to manufacturer copay cards. If your employer’s pharmacy benefit works this way, ask HR or the plan before you rely on the card.

Every manufacturer card excludes people enrolled in government programs, including Medicare, Medicaid, TRICARE and the VA. Our guide on whether insurance covers GLP-1s for weight loss explains prior authorization and appeals.

Medicare: the $50 GLP-1 Bridge

For years, Medicare drug plans could not cover medicines used only for weight loss. That changed, temporarily, on July 1, 2026.

According to CMS and Medicare.gov, the Medicare GLP-1 Bridge is a short-term demonstration that runs from July 1, 2026 to December 31, 2027. Eligible people with Part D coverage pay a $50 copay for a one-month supply of covered drugs. For Zepbound, only the KwikPen is covered; single-dose vials and pens are not.

Important fine print from Medicare.gov and CMS:

• A clinician must submit a prior authorization attesting that you meet the criteria. For example, CMS lists a BMI of 35 or more, or a BMI of 30 or more with heart failure with preserved ejection fraction, uncontrolled high blood pressure or chronic kidney disease stage 3a or above, or a BMI of 27 or more with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. Treatment must be combined with ongoing lifestyle changes.
• The $50 copay does not count toward your Part D deductible or yearly out-of-pocket limit, and Extra Help cannot lower it.
• People prescribed tirzepatide for an already-covered condition, such as moderate-to-severe obstructive sleep apnea, go through their regular Part D plan instead of the Bridge.

At $50 for 13 fills, the Bridge works out to about $650 a year for the medicine, less than an eighth of the self-pay total in example B. If you are on Medicare, it is worth asking your clinician whether you qualify before paying cash.

Mounjaro is the same molecule, but a different product

Mounjaro contains tirzepatide too, but it is FDA-approved for type 2 diabetes, not chronic weight management. For people without diabetes, prescribing it only for weight loss is off-label. Our Zepbound vs Mounjaro guide covers the label differences.

On price, Mounjaro is generally not the cheaper route. An independent tracker that recorded prices from sellers’ own pages on October 3, 2026 listed Mounjaro at $499 a month for all strengths on TrumpRx.gov, the federal government’s drug-price site, and a list price of about $1,112 per 28-day fill. That $499 is higher than Zepbound’s self-pay price at every dose except a late 7.5 mg refill (also $499).

Compounded tirzepatide: cheaper, but not FDA-approved

During the shortage years, many telehealth companies sold compounded tirzepatide at prices well below brand-name medicine. That window has largely closed, at least legally.

The FDA determined on December 19, 2024 that the tirzepatide injection shortage was resolved. It gave state-licensed compounding pharmacies until February 18, 2025 and larger outsourcing facilities until March 19, 2025 before ending its enforcement flexibility. Compounded products are still advertised, and some patients on X describe rotating between compounding pharmacies “as they shut down.”

The FDA’s position is direct: compounded drugs “are not FDA approved,” and the agency does not review them for safety, effectiveness or quality. As of May 31, 2026, it had received more than 730 adverse event reports associated with compounded tirzepatide, and it notes such events are likely underreported. It has also warned about fraudulent labels naming pharmacies that never made the product, dosing errors, poorly refrigerated shipments, and products sold “for research purposes.”

The FDA’s own list of telehealth red flags includes prices “that seem too good to be true” and claims that a compounded drug is the same as an FDA-approved one. With brand-name Zepbound now available for $299 to $449 a month, the price gap is much narrower than it was in 2024.

HSA, FSA and taxes

IRS Publication 502 says you can include amounts paid for prescribed medicines as medical expenses. It also says costs to lose weight count when the weight loss “is a treatment for a specific disease diagnosed by a physician (such as obesity, hypertension, or heart disease).”

In practice, many people pay for prescribed tirzepatide with a health savings account (HSA) or flexible spending account (FSA). Your plan administrator may ask for the prescription, a receipt that shows the drug, or a letter of medical necessity. For an itemized tax deduction, only the part of total medical expenses above 7.5% of adjusted gross income counts. Rules differ by plan, so check with your administrator or a tax professional.

What people are saying, and what to double-check

Price talk on X is a mix of relief and frustration. One person posted that $400 a month for 5 mg was “so worth it.” Another, a retiree who had been on tirzepatide for over a year, wrote that they cannot afford $399 a month. A health-policy researcher pointed to Lilly’s report that 55% of new Zepbound prescriptions in the first quarter of 2026 were self-pay, a sign of how many people are paying cash.

Three habits keep social-media numbers from misleading you:

1. Check the date. A price from 2025 or early 2026 may be out of date. The 45-day program for higher doses began on February 23, 2026, and retail KwikPen self-pay pricing started in March 2026.
2. Check the format. Vial, KwikPen and single-dose pen prices follow different rules.
3. Check what is included. A telehealth “all-in” quote may bundle the medicine with a membership, or may cover only the membership.

How to get an accurate quote

1. Ask your clinician which product and format they intend to prescribe (vial, KwikPen or single-dose pen) and the expected starting dose.
2. Look up the current self-pay price on Lilly’s pages and read the date on the terms.
3. If you will use a retail pharmacy, ask whether it accepts the KwikPen self-pay savings card, and have it run before paying.
4. Ask the prescriber or telehealth service for their visit or membership fee in writing, separate from the medicine.
5. Put a reminder in your calendar a week before each refill is due, so you stay inside the 45-day window.
6. If you are on Medicare, ask about the GLP-1 Bridge before paying cash.

Our step-by-step guide to getting a GLP-1 prescription and our explainer on how telehealth weight-loss programs work cover the visit side.

How tirzepatide compares with semaglutide on price

For comparison, self-pay Wegovy (semaglutide) injections are listed at $349 a month after a $199 introductory price, and the Wegovy pill starts at $149, as we detail in Semaglutide Cost Without Insurance. At most maintenance doses, self-pay Zepbound costs about $100 more per month than standard Wegovy.

Price is only one factor. In the SURMOUNT-5 head-to-head trial, people on tirzepatide lost more weight on average than those on semaglutide, and the two drugs differ in side effects and dosing. Our summary of tirzepatide clinical trial results and what tirzepatide is and how it works give the clinical side. For a side-by-side overview, see the semaglutide vs tirzepatide guide. The right medicine is a decision for you and your clinician, not a spreadsheet.

Thinking long term

Trials show that weight often returns when tirzepatide is stopped. In SURMOUNT-4, people switched to placebo after 36 weeks regained a substantial share of the weight they had lost. That makes cost a long-term question, not a one-month one. Before you start, it is reasonable to ask yourself whether the monthly price is sustainable for a year or more, and to discuss with your clinician what a plan would look like if your budget or coverage changed. Our guide to maintaining weight loss covers the habits that help whichever path you choose.

The bottom line

Without insurance, Zepbound costs $299 at the 2.5 mg starting dose, $399 at 5 mg, and $449 at 7.5 mg to 15 mg if you refill within 45 days, rising to $699 for higher doses when a refill is late. Budget for 13 fills a year, plus needles, prescriber fees and tax, which puts a typical first year at roughly $5,000 to $5,700 for the medicine alone. Commercially insured patients whose plan covers Zepbound may pay as little as $25, and eligible Medicare Part D members can pay $50 a month through the Bridge until the end of 2027. Compounded versions cost less but are not FDA-approved.

Keep exploring in the GLP-1 costs hub, the GLP-1 cost guide and the Tirzepatide hub.

Medical disclaimer: Weightomics publishes general health information for education only. It is not a substitute for professional medical, financial or tax advice, diagnosis or treatment. Never start, stop or change a medication or dose without talking to a licensed clinician. Prices cited were reviewed October 21, 2026 and may change without notice.